Limits...
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF - Cancer (2011)

Bottom Line: Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient outcomes.However, increasing evidence supports the use of specific treatments for certain histological subtypes of STS, and novel therapies, including tyrosine kinase and mammalian target of rapamycin inhibitors, are currently under active investigation.This article provides an overview of current systemic therapies for patients with advanced STS and discusses ongoing efforts designed to improve patient outcomes through the use of novel therapeutic agents and treatment strategies.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. richard.riedel@duke.edu

Show MeSH

Related in: MedlinePlus

The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) study scheme is shown. CR indicates complete response; PR, partial response; SD, stable disease; CT, chemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3412982&req=5

fig02: The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) study scheme is shown. CR indicates complete response; PR, partial response; SD, stable disease; CT, chemotherapy.

Mentions: The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) trial, one of the largest studies of patients with metastatic STS or bone sarcoma published to date, is a pivotal phase 3 trial that evaluated maintenance therapy with oral ridaforolimus in patients (N = 711) who achieved a favorable response (CR, PR, or SD) after receiving a minimum of 4 cycles of chemotherapy (Fig. .2). Preliminary data have demonstrated a significant increase in PFS (ridaforolimus vs placebo), with a 21% improvement in the median PFS (17.7 weeks vs 14.6 weeks; hazard ratio [HR], 0.72 [P = .0001]) and a nonstatistically significant trend toward an OS benefit (21.4 months vs 19.2 months; HR, 0.88 [P = .2256]).109 The incidence of stomatitis and other AEs was higher in patients receiving ridaforolimus, and the overall safety profile was considered to be similar to that of other mTOR inhibitors. Further studies will help confirm the benefit of maintenance therapy with mTOR inhibitors in patients with advanced STS.


Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF - Cancer (2011)

The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) study scheme is shown. CR indicates complete response; PR, partial response; SD, stable disease; CT, chemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3412982&req=5

fig02: The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) study scheme is shown. CR indicates complete response; PR, partial response; SD, stable disease; CT, chemotherapy.
Mentions: The Sarcoma Multi-center Clinical Evaluation of the Efficacy of Ridaforolimus (SUCCEED) trial, one of the largest studies of patients with metastatic STS or bone sarcoma published to date, is a pivotal phase 3 trial that evaluated maintenance therapy with oral ridaforolimus in patients (N = 711) who achieved a favorable response (CR, PR, or SD) after receiving a minimum of 4 cycles of chemotherapy (Fig. .2). Preliminary data have demonstrated a significant increase in PFS (ridaforolimus vs placebo), with a 21% improvement in the median PFS (17.7 weeks vs 14.6 weeks; hazard ratio [HR], 0.72 [P = .0001]) and a nonstatistically significant trend toward an OS benefit (21.4 months vs 19.2 months; HR, 0.88 [P = .2256]).109 The incidence of stomatitis and other AEs was higher in patients receiving ridaforolimus, and the overall safety profile was considered to be similar to that of other mTOR inhibitors. Further studies will help confirm the benefit of maintenance therapy with mTOR inhibitors in patients with advanced STS.

Bottom Line: Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient outcomes.However, increasing evidence supports the use of specific treatments for certain histological subtypes of STS, and novel therapies, including tyrosine kinase and mammalian target of rapamycin inhibitors, are currently under active investigation.This article provides an overview of current systemic therapies for patients with advanced STS and discusses ongoing efforts designed to improve patient outcomes through the use of novel therapeutic agents and treatment strategies.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. richard.riedel@duke.edu

Show MeSH
Related in: MedlinePlus